Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab + FOLFIRI versus cetuximab/bevacizumab + FOLFIRI in recurrent RAS/BRAF wild-type metastatic colorectal cancer
NL-OMON60039Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amivantamab in colorectal cancer (CRC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Progression-free survival and Overall survival. Started Apr 2025; status: recruiting.
02
Drugs
amivantamab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON60039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60039.